Forecast

There is no analyst data available for this company.

Discussions in the community

There is no discussion about this asset yet.

Start discussion

  • Photocure increases currency-adjusted product revenue by 18% in Q1 2026

    Photocure reports currency-adjusted product revenue growth of 18% for Q1 2026 and total revenue of NOK 264.6 million, significantly beating analyst estimates. Drivers were accelerated adoption of blue-light cystoscopy (BLC) in North America (26%) and Europe (11%) as well as milestone payments from partner Asieris. Adjusted EBITDA improved to NOK 15.3 million (Marche 11%), but reported EPS was -0.01 and missed expectations. Photocure confirms its 2026 guidance with expected currency-adjusted product revenue growth of 7–11% and further expansion of its market position for BLC. » More on de.investing.com


  • Photocure exceeds sales expectations in Q2 2025 and shares rise sharply

    Photocure surpassed forecasts in the second quarter of 2025 with revenue of NOK 135.6 million, achieving 11% growth. The company reported positive EBITDA and a 12.01% increase in its share price, driven by strong results in North America and Europe as well as innovative product developments. Management confirmed its growth outlook and emphasized a strategic focus on expansion and partnerships. » More on de.investing.com


  • Photocure achieves record revenue in the second quarter of 2025 and focuses on strategic expansion

    Photocure reported record revenue of NOK 135.6 million in the second quarter of 2025, representing 11% growth year-on-year. The company benefited from strong performance in North America and Europe, improved operational efficiency, and strategic partnerships and expansions, particularly in the US, Europe, and China. Photocure confirmed its 2025 outlook and believes it is well positioned for further growth through investments and innovation. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2013, PhotoCure has already paid €0.26 in dividends. The last payout was in June 2013.

Financials

In the last quarter, PhotoCure had revenue of €12.93m and net profit of -€2.4m

(EUR) September 2026
YoY
Revenue 12.93m 12.30%
Gross profit 11.34m 14.89%
Net profit -2.4m 807.67%
EBITDA 3.95m 220.87%

Fundamentals

Metric Value
Market capitalization
€102.85m
Number of shares
26.97m
52-week high/low
€7.43 - €3.81
Dividends No
Beta
0.35
P/E ratio
22.37
PEG ratio
0.00
P/B ratio
1.91
P/S ratio
1.62

Company profile

Photocure ASA, a specialty pharmaceutical company, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products in Nordic countries, Germany, France, Austria, the United Kingdom, the Netherlands, Italy, other European Countries, and the United States. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It also develops Cevira for the treatment of human papilloma virus infection and precancerous lesions of the cervix. The company sells its products to pharmaceutical wholesalers, pharmacies, and hospitals through license partners. Photocure ASA was founded in 1993 and is headquartered in Oslo, Norway.

Name
PhotoCure
CEO
Daniel Schneider
Headquarters Oslo, ps
Norway
Website
IPO
30/05/2000
Employees 101

Ticker symbols

Exchange Symbol
Osl
PHO.OL
London Stock Exchange
0IMT.L
Pnk
PHCUF
Frankfurt
PHS.F
Düsseldorf
PHS.DU
London
0IMT.L
🍪

Parqet  uses cookies. Learn more